NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Interventional Procedures Advisory Committee (IPAC) meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday, 08 December 2022

**Location:** Via Zoom

# Committee members present

1. Professor Tom Clutton-Brock [Chair] Present for all items
2. Professor Colin Howie [Vice Chair] Present for all items
3. Dr Charlotta Karner Present for all items
4. Ms Dawn Lee Present for all items except item 6 (part 2)
5. Mr James Tysome Present for all items
6. Miss Karen Nugent Present for items 5, 6, 7, 8, and 9
7. Mr Kieran Murphy Present for all items except item 6
8. Mr Mahmoud Elfar Present for items 3 and 4
9. Ms Maria Parsonage Present for all items
10. Professor Matt Bown Present for all items
11. Mr Patrick Farrell Present for all items
12. Dr Paula Whittaker Present for all items
13. Mrs Sally Brearley Present for all items except item 5
14. Dr Stuart Smith Present for all items
15. Professor Tim Jackson Present for item 3
16. Professor Tim Kinnaird Present for all items
17. Ms Veena Soni Present for all items except item 3

# Committee Apologies

1. Professor Dhiraj Tripathi
2. Dr Greg Irving
3. Dr Jon Bell
4. Dr Jurjees Hasan
5. Mr Marwan Habiba
6. Mr Matthew Metcalfe
7. Mr Mustafa Zakkar

# NICE staff present:

Dr Alan Ashworth – Consultant Clinical Advisor, IPP

Amy Crossley – HTA Advisor, IPP

Anastasia Chalkidou – Associate Director, IPP

Anna Sparshatt – Senior Editor, Publishing

Charlie Campion – Project Manager, IPP

Deonee Stanislaus – Coordinator, IPP

Emilene Coventry – Senior Medical Editor, Publishing

Harriet Edmondson – SPR Public Health, Managed Access

Hazmin Ahamed - Senior Business Analyst, Transformation Programme

Helen Crosbie – Public Involvement Advisor, Public Involvement Programme

Helen Gallo – Senior Health Technology Assessment Analyst, IPP

Professor John Powell – Consultant Clinical Advisor, IPP

Professor Kevin Harris – Programme Director & Consultant Clinical Advisor, IPP

Lakshmi Mandava – Health Technology Assessment Analyst, IPP

Lyn Davies – Coordinator, Corporate Office

Oyewumi Afolabi - PASLU Technical Analyst, Commercial Liaison team

Rosalee Mason – Coordinator, Corporate Office

Sammy Shaw – Associate Health Technology Assessment Analyst, IPP

Suzi McFall – Specialist Registrar, Managed Access

Xia Li – Health Technology Assessment Analyst, IPP

Zoe Jones – Administrator, IPP

Ziqi Zhou - Associate Health Technology Assessment Analyst, IPP

#

# External group representatives present:

Ami Scott, BSCI Present for item 3

Kirsty Macara, BSCI Present for item 3

Harvey Galvin, AngioDynamics Present for item 4

George Malone, Penumbra Present for item 4

Alain Cornil, Penumbra Present for item 4

Dr Thomas Tu, Inari Medical Present for item 4

Daniel Adam-Blanco, Inari Medical Present for item 4

Vanessa DeBruin, Medtronic Present for item 6

Heidrun Behrmann, Medtronic Present for item 6

Samuel Carter, ReCor Medical Present for item 6

Neil Barman, ReCor Medical Present for item 6

Reinhard Krickl, Phagenesis Present for item 7

Conor Mulrooney, Phagenesis Present for item 7

# Clinical & patient experts present:

Wing Yan Liu, Consultant Interventional Radiologist, University Hospitals Coventry and Warwickshire NHS Trust Present for item 3

John Leeds, Consultant Pancreaticobiliary Physician and Endoscopist, Newcastle Upon Tyne Hospitals NHS Foundation Trust Present for item 3

Emma Wilton, Consultant Vascular Surgeon, Oxford University Hospitals NHS Foundation Trust Present for item 4

David Thompson, Consultant Vascular Radiologist, Manchester University NHS Foundation Trust Present for item 4

Dare Seriki, Consultant Vascular Radiologist, Manchester University NHS Foundation Trust Present for item 4

Jo Jerrome, Chief Executive, Thrombosis UK Present for item 4

Melvin Lobo, Director Barts BP Clinic & Consultant in CV Medicine, Barts Health NHS Trust Present for item 6

Andrew Sharp, Consultant Cardiologist, Cardiff and Vale University Health Board Present for item 6

Philip Bath, Stroke Association Professor of Stroke Medicine, University of Nottingham Present for item 7

1. Introduction to the meeting
	1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
	1. The chair informed the committee that this will be Tim Jackson and Kieran Murphy’s last meeting and thanked them for their contributions to IPAC.
	2. The chair confirmed the advert for Tim Jackson and Colin Howie’s replacements are live. This is for an ophthalmologist and an orthopaedic surgeon to join the committee. The chair encouraged the committee to share the advert with their networks.
	3. The chair advised the committee that we are recruiting for the vice-chair position and encouraged those who are interested in the role to apply.
3. NNP of IP1912 Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis
	1. Part 1 – Open session
		1. The Chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from BSCI.
		2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Tim Jackson, who gave a presentation on the safety and efficacy of Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis.
	1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 9:56.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. NNP of IP1929 Percutaneous thrombectomy for massive pulmonary embolus
	1. Part 1 – Open session
		1. The Chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Angio Dynamics, Penumbra, and Inari Medical.
		2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Tim Kinnaird, who gave a presentation on the safety and efficacy of Percutaneous thrombectomy for massive pulmonary embolus.
	1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 11:36.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. Public Consultation comments of IP269/3 Endoluminal gastroplication for gastro-oesophageal reflux disease
	1. Part 1 – Open session
		1. The Chair welcomed the invited members of the public.
		2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced James Tysome, who summarised the comments received during the consultation on the draft guidance for Endoluminal gastroplication for gastro-oesophageal reflux disease.
		2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
	1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 12:59.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.

		A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>
1. Public Consultation comments of IP923/2 Percutaneous transluminal renal sympathetic denervation for resistant hypertension
	1. Part 1 – Open session
		1. The Chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from ReCor Medical and Medtronic.
		2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.
* Dawn Lee declared a non-financial professional interest as when working in her previous company she provided quality control for Medtronic for the construction of an economic model for the device used in this procedure.
* It was agreed that her declaration would prevent Dawn Lee from participating in part 2 of the discussion for this procedure.
* Kieran Murphy declared a direct financial interest as he is an employee of ReCor Medical.
* It was agreed that his declaration would prevent Kieran Murphy from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Colin Howie, who summarised the comments received during the consultation on the draft guidance for Percutaneous transluminal renal sympathetic denervation for resistant hypertension.
		2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
	1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 13:53.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.

		A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>
1. Public Consultation comments of IP1877 Electrical stimulation of the pharynx for neurogenic dysphagia
	1. Part 1 – Open session
		1. The Chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Phagenesis.
		2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then summarised the comments received during the consultation on the draft guidance for Electrical stimulation of the pharynx for neurogenic dysphagia.
		2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
	1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 14:42.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.

		A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>
1. Public Consultation comments of IP1857 Percutaneous thoracic duct embolization for persistent chyle leak
	1. Part 1 – Open session
		1. The Chair welcomed the invited members of the public.
		2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Karen Nugent, who summarised the comments received during the consultation on the draft guidance for Percutaneous thoracic duct embolization for persistent chyle leak.
		2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
	1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 15:06.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.

		A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Briefs of IP881/2 Carotid artery stent placement for asymptomatic extracranial carotid stenosis
	1. Part 1 – Closed session
		1. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Matt Bown, who gave a presentation on the safety and efficacy of Carotid artery stent placement for asymptomatic extracranial carotid stenosis.
		2. The committee approved the content of the scope as adequate for evaluation of this procedure.
1. Date of the next meeting

The next meeting of the Interventional Procedures Advisory Committee (IPAC) will be held on 12/01/2023 and will start promptly at 9am.